Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Cleveland BioLabs, Inc. (NASDAQ: CBLI), a drug discovery and development company, is focused on using its proprietary discoveries to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The company’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias, while Curaxins are being developed as anticancer agents that may function as mono-therapy drugs. For further information, visit the Company’s web site at www.cbiolabs.com.